is compound semaglutide going away FDA Ends Compounded GLP-1s: What to Know Compounded Semaglutide vs Wegovy |

Fitch CD, Chevli R

47,48 GLP-1 agonists impact the dopamine signaling in the mesolimbic pathway and regulate the reward-motivated behavior in alcohol consumption, thus showing potential as a pharmacotherapeutic intervention

Repetitive injury induces phenotypes associated with Alzheimers disease by reactivating HSV-1 in a human brain tissue model

Wolf always starts with the basics

Several active research areas include: Metabolic dysfunction-associated steatotic liver disease (MASLD) : Multiple trials are evaluating semaglutide's effects on liver fat content and biomarkers, with preliminary data suggesting potential benefits in reducing hepatic steatosis and improving liver enzyme profiles Chronic kidney disease : Studies examining renal outcomes in patients with type 2 diabetes and established kidney disease, building on secondary analyses from SUSTAIN 6 showing reduced progression of diabetic nephropathy Obstructive sleep apnea : Ongoing trials investigating whether weight loss achieved with semaglutide improves sleep apnea severity and related cardiovascular outcomes Addiction and substance use disorders : Early-phase research exploring GLP-1 receptor agonists' potential effects on reward pathways and addictive behaviors, though this remains highly preliminary Alzheimer's disease and cognitive function : Preclinical evidence suggesting neuroprotective properties has prompted clinical trials examining cognitive outcomes in at-risk populations Researchers are also investigating combination therapies , such as cagrilintide plus semaglutide (CagriSema), which is currently under development